Wuhan Kangfude Biotechnology Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Wuhan Kangfude Biotechnology Co., Ltd. - overview
Established
2010
Location
Wuhan, Hubei, China
Primary Industry
Biotechnology
About
Founded in 2010 and based in Wuhan, China, Wuhan Kangfude Biotechnology Co. , Ltd. is a biotech company that focuses on the research and development of new oral enzyme drugs and oral microecological new drugs. In 2015, the company was listed on the National Equities Exchange and Quotations System.
Its stock code is 832036. Dr. Qingshan Li, the founder of the company, founded Captozyme. The company's main products include oxalate decarboxylase TRA16, new drugs for hyperuricemia and gout microecology.
The oxalate decarboxylase TRA16 can degrade oxalate in food. The company's products are used in diseases such as urinary calculi, hyperoxalemia and gout.
Current Investors
Prosperity Investment
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.kfdbio.com
Verticals
HealthTech
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.